menu
    • menu

    Company profile for Nested Therapeutics

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are Nested Therapeutics, a biotech company inspired by service and driven by a desire to make a meaningful impact. We are creative innovators who challenge our own assumptions as we strive to find new, overlooked areas of opportunity to design therapeutics for a perfect fit. We embrace diverse perspectives and experiences in a space for everyone to add value and be valued in return, with the purpose of building solutions to...
    We are Nested Therapeutics, a biotech company inspired by service and driven by a desire to make a meaningful impact. We are creative innovators who challenge our own assumptions as we strive to find new, overlooked areas of opportunity to design therapeutics for a perfect fit. We embrace diverse perspectives and experiences in a space for everyone to add value and be valued in return, with the purpose of building solutions together while having fun doing it. United through our common vision for the future of precision medicine and our shared values of service, humility, impact, invention, and connection.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nested TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Cambridge, MA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://nestedtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/nestedtx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nested Announces Presentation of NST-628 at the 2024 AACR
    Nested Announces Presentation of NST-628 at the 2024 AACR

    08 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nested-therapeutics-announces-oral-presentation-of-preclinical-data-for-nst-628-a-novel-fully-brain-penetrant-pan-rafmek-molecular-glue-at-the-2024-aacr-annual-meeting-302110793.html

    PR NEWSWIRE
    08 Apr 2024
    Share Share
    Nested to Present Preclinical Data for NST-628 at 2024 AACR Annual Meeting
    Nested to Present Preclinical Data for NST-628 at 2024 AACR Annual Meeting

    28 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nested-therapeutics-to-present-preclinical-data-for-nst-628-a-novel-pan-rafmek-molecular-glue-in-the-new-drugs-on-the-horizon-series-at-2024-aacr-annual-meeting-302101828.html

    PR NEWSWIRE
    28 Mar 2024
    Share Share
    Nested Announces FDA Clearance of IND Application for NST-628
    Nested Announces FDA Clearance of IND Application for NST-628

    28 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nested-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-nst-628-a-novel-pan-rafmek-molecular-glue-302101827.html

    PR NEWSWIRE
    28 Mar 2024
    Share Share
    Nested Therapeutics Presents First Preclinical Data for Lead Candidate, NST-628
    Nested Therapeutics Presents First Preclinical Data for Lead Candidate, NST-628

    12 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nested-therapeutics-presents-first-preclinical-data-for-lead-candidate-nst-628-a-rasmapk-pathway-inhibitor-at-2023-aacr-nci-eortc-conference-301953990.html

    PR NEWSWIRE
    12 Oct 2023
    Share Share
    Nested Therapeutics to Present Preclinical Data for RAS/MAPK Pathway
    Nested Therapeutics to Present Preclinical Data for RAS/MAPK Pathway

    04 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nested-therapeutics-to-present-preclinical-data-for-novel-potential-best-in-class-inhibitor-of-the-rasmapk-pathway-at-2023-aacr-nci-eortc-conference-301947339.html

    PR NEWSWIRE
    04 Oct 2023
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Nested Therapeutics FDA Clearance for NST-628, a Pan-RAF/MEK Molecular Glue

    Details:

    NST-628 is a novel pan-RAF/MEK molecular glue targeting the RAS-MAPK pathway, evaluated for RAS-MAPK mutated advanced solid tumors.


    Lead Product(s): NST-628

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 28, 2024

    blank

    01

    Nested Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Nested Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : NST-628

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Nested Therapeutics FDA Clearance for NST-628, a Pan-RAF/MEK Molecular Glue

    Details : NST-628 is a novel pan-RAF/MEK molecular glue targeting the RAS-MAPK pathway, evaluated for RAS-MAPK mutated advanced solid tumors.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 28, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

    Details:

    NST-628 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.


    Lead Product(s): NST-628

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 22, 2024

    blank

    02

    Nested Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Nested Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : NST-628

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumo...

    Details : NST-628 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 22, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Nested Therapeutics Launches With $125 Million Financing

    Details:

    The financing will enable Nested to advance its pipeline including NEST-1, and further develop its platform that reveals cryptic, or newly uncovered, driver mutations and pockets in high-conviction cancer targets to dramatically expand the reach of precision medicine.


    Lead Product(s): NEST-1

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Miscellaneous

    Sponsor: Versant Ventures

    Deal Size: $125.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing October 06, 2022

    blank

    03

    Nested Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Nested Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : NEST-1

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Versant Ventures

    Deal Size : $125.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Nested Therapeutics Launches With $125 Million Financing

    Details : The financing will enable Nested to advance its pipeline including NEST-1, and further develop its platform that reveals cryptic, or newly uncovered, driver mutations and pockets in high-conviction cancer targets to dramatically expand the reach of preci...

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    October 06, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search